Vaccines - Ukraine

Ukraine

In Ukraine, the Vaccines market is expected to achieve a revenue of US$104.10m by 2025.
It is projected to experience an annual growth rate (CAGR 2025-2029) of -3.29%, leading to a market volume of US$91.06m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of US$29,970.00m in 2025.
Ukraine's vaccine market is witnessing a surge in demand due to increasing awareness and government initiatives.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Ukraine has been on the rise in recent years due to various reasons.

Customer preferences: Ukrainians have become more health-conscious and are now more willing to invest in their health. The COVID-19 pandemic has also played a significant role in increasing the demand for vaccines. People are now more aware of the importance of vaccines in preventing diseases and are willing to take them.

Trends in the market: The vaccines market in Ukraine has been growing steadily in recent years. The government has been investing heavily in the healthcare sector, which has led to the development of better healthcare facilities and an increase in the availability of vaccines. The private sector has also been playing a significant role in the market, with many companies investing in research and development of new vaccines.

Local special circumstances: Ukraine has been facing several health challenges in recent years, including a high incidence of infectious diseases such as measles, hepatitis, and tuberculosis. The government has been working to address these challenges by investing in the healthcare sector and increasing the availability of vaccines. The conflict in eastern Ukraine has also led to an increase in the demand for vaccines, as people are more vulnerable to diseases in conflict zones.

Underlying macroeconomic factors: The Ukrainian economy has been growing steadily in recent years, which has led to an increase in the disposable income of the population. This has made it easier for people to invest in their health and has led to an increase in the demand for vaccines. The government's efforts to improve the healthcare sector have also had a positive impact on the market. However, the market still faces several challenges, including a lack of access to vaccines in rural areas and a lack of awareness about the importance of vaccines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.